With less than a year until the UK exits the European Union, the CDMO company has established a taskforce to manage the potential impact of Brexit on its organisation.
The formation of the ‘Brexit taskforce’ will see Recipharm prioritize its preparations and invest in the necessary capabilities and equipment within its UK and European facilities to ensure seamless operations post March 2019, reports the company.
There is a risk of a “hard” Brexit
“While many stakeholders in the pharma industry are campaigning for a ‘soft’ exit from the EU, there is a risk that the complexity of the regulatory landscape will increase dramatically if a ‘hard’ Brexit takes place. Consequently, we are preparing for all eventualities,” said Thomas Beck, Senior Vice President Quality Management at Recipharm. “Recipharm’s presence in both the UK and mainland Europe means we are well positioned to support our customers post-Brexit. We are also adept at streamlining processes across geographies and dealing with third party importations into Europe due to our global facilities.”
To strengthen its organisation ahead of Brexit, Recipharm has plans to recruit more staff in laboratory and regulatory roles to meet the additional analytical, release testing and administration requirements that are expected.
“Brexit has the potential to bring about additional resource demands. We are focused on ensuring our team is equipped to handle the potential challenges so that our customers continue to receive the same level of service. We also expect to see a greater demand for outsourced manufacturing services from UK-based marketing authorization holders (MAHs) wishing to supply to Europe and are preparing our team to meet this demand,” says Beck. “We firmly believe that the challenge needs to be faced in a pragmatic way and have been liaising with both the EMA and relevant politicians to communicate that the finer details of Brexit and the implications on our industry need to be discussed as a matter of priority.”
Read more about Brexit: